Advertisement
UK markets open in 5 hours 21 minutes
  • NIKKEI 225

    37,892.10
    -567.98 (-1.48%)
     
  • HANG SENG

    17,144.12
    -57.15 (-0.33%)
     
  • CRUDE OIL

    82.77
    -0.04 (-0.05%)
     
  • GOLD FUTURES

    2,330.90
    -7.50 (-0.32%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,726.67
    -1,865.61 (-3.48%)
     
  • CMC Crypto 200

    1,394.31
    -29.79 (-2.09%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects

Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects

Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.